Skip to main content
Fig. 8 | Molecular Medicine

Fig. 8

From: Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson’s disease models in vitro and vivo

Fig. 8

The content of TH and GFAP in striatum of rotenone-induced PD mouse model transduced with NDI1. A TH content in stratum (i.e. the content of dopamine) was examined by immunohistochemistry. The striatum sections were stained with TH antibody (brown). Scale bar = 500 μm. B GFAP (glial fibrillary acidic protein) content in stratum was examined by immunohistochemistry. The striatum sections were stained with GFAP antibody (brown). Scale bar = 500 μm. C, D TH (tyrosine hydroxylase) staining intensity was quantified by ImageJ software. The TH-positive optical density values in the left and right striatum were subjected to statistical analysis. E, F GFAP staining intensity was quantified by ImageJ software. The GFAP-positive optical density values in the left and right striatum were subjected to statistical analysis. Rotenone + vector group compared with DMSO + vector group, or Rotenone + NDI1 group compared with Rotenone + vector group, or Rotenone + NDI1 group compared with DMSO + vector group, ns not significant, **P < 0.01, ***P < 0.001

Back to article page

Molecular Medicine

ISSN: 1528-3658